PATIENTS

Our Priority is to Put You at the Center

At Alnylam, we want to understand your journey, your experiences, and your unique needs. You inspire us to learn as much as we can, to persevere and continue to advance the development of potential therapies to treat rare and serious diseases. We take pride in working together to achieve mutual goals such as increasing awareness, enabling diagnosis, and providing education and services to support patient communities. We have a dedicated team to ensure your perspectives are represented at Alnylam. If you are an advocate interested in helping us increase awareness of rare diseases, please send an email to PatientAdvocacy@alnylam.com

Understanding RNAi

RNA interference (RNAi) is the core discovery that forms the therapies Alnylam is developing. It is recognized as a major scientific breakthrough—but how does it work, exactly?

From Possibility to Patients: Understanding RNAi

Learn about RNAi and our investigational therapies

Read More >

Alnylam is focused on 3 Strategic Therapeutic Areas (STArs):
genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases

Start Here >

Alnylam is dedicated to providing support for affected individuals, families, and caregivers

About Alnylam Act >

Interested in our clinical trials program?

Read More >

PATISIRAN’S EXPANDED
ACCESS PROGRAM

Alnylam supports eligible individuals with the Expanded Access Program aimed to help those living with hATTR amyloidosis with polyneuropathy gain access to patisiran. Speak with your medical professional to learn more about the program and your eligibility.

OUR

 FOCUS ON YOU

Leo: Living With hATTR Amyloidosis

Get more information about hATTR Amyloidosis.

Start Here >

Rose & Colin: Living With Porphyria

Get more information about Porphyria.

Start Here >

Venkat: Living With Hemophilia

Get more information about Hemophilia.

Start Here >

Access to
Investigational Drugs

Alnylam is dedicated to developing new therapies that have a positive impact on patient health, and to serving patients, patient families and patient communities through education, empathy, and awareness. We understand that there are seriously ill patients who will not be eligible for our clinical trials and may not have options for alternative therapies, including investigational therapies in trials being conducted by other sponsors. In these circumstances, Alnylam will consider providing a requesting physician with pre-approval access to a specific Alnylam investigational drug, for the treatment of an individual patient outside of a clinical trial, when certain conditions are met.

CLINICAL TRIALS

Interested in learning about our hATTR amyloidosis studies? Get started here.

Learn More >

PATIENT ADVOCACY

At Alnylam, we put you at the center of everything we do. We have a team dedicated to collaborating with patient advocacy groups and individuals affected by these rare diseases.

Read More >

SIGN UP FOR PATIENT CONNECT

Receive updates on our investigational therapies and clinical trials.